Pamela Munster, MD
Professor
Medicine
School of Medicine

Education & Training

Show all (3) Hide

• Fellowship Hematology-Oncology Memorial Sloan-Kettering Cancer Center 2000
• Residency Internal Medicine Indiana University School of Medicine 1996
• University of Bern 1989

Websites

Show all (2) Hide

• Pamelamunster.org (Pamelamunster.org)
• Profile at UCSF Cancer Center (cancer.ucsf.edu)

Grants and Projects

Show all (8) Hide

• Integrating Epigenetic Modulation into DNA Damage Repair, NIH, 2022-2027
• Cancer Center Support Grant, NIH, 1999-2023
• Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer, NIH, 2017-2022
• Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition, NIH, 2014-2020
• The role of HDAC2 in hormone therapy resistance, NIH, 2011-2017
• The Role of Selective HDAC Enzymes in Drug Sensitivity, NIH, 2007-2012
• Potentiation of Topo Inhibitors by the HDACi, SAHA, NIH, 2006-2008
• Potentiation of Topo Inhibitors by HDAC Inhibitors, NIH, 2004-2007

Publications (161)

Top publication keywords:
TrastuzumabTamoxifenAntineoplastic Agents, HormonalReceptors, GlucocorticoidBRCA1 ProteinBreast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAmenorrheaBRCA2 ProteinAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsHydroxamic AcidsEpirubicinHistone Deacetylase Inhibitors

• Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant.
  Scientific reports 2025 Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN
• Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors.
  Breast cancer research : BCR 2025 Pacaud R, Thomas S, Chaudhuri S, Lazar A, Timmerman LA, Munster PN
• A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
  European journal of cancer (Oxford, England : 1990) 2024 Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, Spreafico A, Subbiah V, Illert AL, Tan D, Santoro A, Munster PN, Suehiro Y, Wang Y, Ji DM, Chen S, Beltz K, Suenaga N, Ramkumar T, Luo F, …
• Estrogens and breast cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2024 Kim J, Munster PN
• Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
  JCO precision oncology 2024 Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN

Show all (156 more) Hide

• ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.
  Cancer research communications 2024 Chen CT, Khanna V, Kummar S, Abdul-Karim RM, Sommerhalder D, Tolcher AW, Ueno NT, Davis SL, Orr DW, Hamilton E, Patel MR, Spira AI, Jauhari S, Florou V, Duff M, Xu R, Wang J, Barkund SR, Zhou H, …
• A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
  Cancer research communications 2024 Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P,…
• Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
  JCO precision oncology 2024 Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P
• First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
  Cancer research communications 2024 Yarchoan M, Powderly JD, Bastos BR, Karasic TB, Crysler OV, Munster PN, McKean MA, Emens LA, Saenger YM, Ged Y, Stagg R, Smith S, Whiting CC, Moon A, Prasit P, Jenkins Y, Standifer N, Dubensky TW, …
• Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
  Cancer research communications 2024 Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S
• Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Carneiro BA, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma WW, Coveler AL, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weisskittel T, Li H, Borden BA, Harvey RD, …
• Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
  Cancer research communications 2023 Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S
• A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
  Targeted oncology 2023 Razak ARA, Wang HM, Chang JY, Ahn MJ, Munster P, Blumenschein G, Solomon B, Lim DW, Hong RL, Pfister D, Saba NF, Lee SH, van Herpen C, Quadt C, Bootle D, Blumenstein L, Demanse D, Delord JP
• A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models.
  Research square 2023 Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN
• First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Prostatectomy.
  European urology oncology 2023 Nguyen HG, van den Berg NS, Antaris AL, Xue L, Greenberg S, Rosenthal JW, Muchnik A, Klaassen A, Simko JP, Dutta S, Sorger JM, Munster P, Carroll PR
• Vaccinia (Smallpox) for the Treatment of Ovarian Cancer-Turning an Old Foe Into a Friend?
  JAMA oncology 2023 Tsang ES, Munster PN
• Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
  British journal of cancer 2023 Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK
• ATM-SPARK: A GFP phase separation-based activity reporter of ATM.
  Science advances 2023 Li X, Chung CI, Yang J, Chaudhuri S, Munster PN, Shu X
• Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead.
  OncoTargets and therapy 2022 Tsang ES, Munster PN
• Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Munster PN, Greenstein AE, Fleming GF, Borazanci E, Sharma MR, Custodio JM, Tudor IC, Pashova HI, Shepherd SP, Grauer A, Sachdev JC
• Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK
• A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
  Cancer research communications 2022 Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN
• Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma.
  American journal of medical genetics. Part A 2022 Modlin EW, Slavotinek AM, Darling TN, Lipkowitz S, Barr FG, Munster PN, Biesecker LG, Ours CA
• Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies.
  Neuro-oncology advances 2022 Odia Y, Cavalcante L, Safran H, Powell SF, Munster PN, Ma WW, Carneiro BA, Bastos BR, Mikrut S, Mikrut W, Giles FJ, Sahebjam S
• Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
  Frontiers in endocrinology 2022 Pivonello R, Munster PN, Terzolo M, Ferrigno R, Simeoli C, Puglisi S, Bali U, Moraitis AG
• Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
  The Lancet. Oncology 2021 Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, …
• A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, Dunphy M, Le MH, Molineaux C, Orford K, Parlati F, Whiting SH, Bennett MK, Tannir NM, Meric-Bernstam F
• Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
  Blood cancer discovery 2021 Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye…
• Specialized computational methods for denoising, B1 correction, and kinetic modeling in hyperpolarized 13 C MR EPSI studies of liver tumors.
  Magnetic resonance in medicine 2021 Lee PM, Chen HY, Gordon JW, Zhu Z, Larson PEZ, Dwork N, Van Criekinge M, Carvajal L, Ohliger MA, Wang ZJ, Xu D, Kurhanewicz J, Bok RA, Aggarwal R, Munster PN, Vigneron DB
• Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
  Cancer 2021 Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A
• Immunotherapy in breast cancer: A clinician's perspective.
  Journal of the National Cancer Center 2021 Chaudhuri S, Thomas S, Munster P
• Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target.
  Melanoma research 2021 Bao R, Surriga O, Olson DJ, Allred JB, Strand CA, Zha Y, Carll T, Labadie BW, Bastos BR, Butler M, Hogg D, Musi E, Ambrosini G, Munster P, Schwartz GK, Luke JJ
• A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
  Oral oncology 2021 Jelinek MJ, Foster NR, Zoroufy AJ, Schwartz GK, Munster PN, Seiwert TY, de Souza JA, Vokes EE
• Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
  Breast cancer research and treatment 2020 Sachdev JC, Munster P, Northfelt DW, Han HS, Ma C, Maxwell F, Wang T, Belanger B, Zhang B, Moore Y, Thiagalingam A, Anders C
• Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
  Frontiers in immunology 2020 De Souza A, Tavora FA, Mahalingam D, Munster PN, Safran HP, El-Deiry WS, Carneiro BA
• Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
  Journal for immunotherapy of cancer 2020 Siu L, Brody J, Gupta S, Marabelle A, Jimeno A, Munster P, Grilley-Olson J, Rook AH, Hollebecque A, Wong RKS, Welsh JW, Wu Y, Morehouse C, Hamid O, Walcott F, Cooper ZA, Kumar R, Ferté C, Hong DS
• KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
  The New England journal of medicine 2020 Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, …
• Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
  Nature communications 2020 Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN
• Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
  Nature communications 2020 Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, …
• Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
  Nature communications 2020 Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, …
• First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.
  Cancer management and research 2019 Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan…
• Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials.
  JCO oncology practice 2019 Garrett SB, Matthews TM, Abramson CM, Koenig CJ, Hlubocky FJ, Daugherty CK, Munster PN, Dohan D
• Reply: Strategies to Prevent Cardiotoxicity.
  Journal of the American College of Cardiology 2019 Guglin M, Tamura R, Krischer J, Munster PN
• Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK
• A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
  PloS one 2019 Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M
• Maintenance lenalidomide in primary CNS lymphoma.
  Annals of oncology : official journal of the European Society for Medical Oncology 2019 Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B
• Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
  JAMA oncology 2019 Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'…
• A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
  Oncology 2019 Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E
• Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
  Journal of the American College of Cardiology 2019 Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN
• Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C
• A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.
  Pigment cell & melanoma research 2019 Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A
• Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies.
  Journal of magnetic resonance (San Diego, Calif. : 1997) 2019 Zhu Z, Zhu X, Ohliger MA, Tang S, Cao P, Carvajal L, Autry AW, Li Y, Kurhanewicz J, Chang S, Aggarwal R, Munster P, Xu D, Larson PEZ, Vigneron DB, Gordon JW
• Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
  British journal of cancer 2018 Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD
• Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
  Blood advances 2018 Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, …
• A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
  Annals of oncology : official journal of the European Society for Medical Oncology 2018 Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P
• Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, Le Tourneau C, O'Neil B, Mathijssen RHJ, Lopez-Martin JA, Edenfield WJ, Martin M, LoRusso PM, Bray GL, DiMartino J, Nguyen A, …
• Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, …
• Technique development of 3D dynamic CS-EPSI for hyperpolarized 13 C pyruvate MR molecular imaging of human prostate cancer.
  Magnetic resonance in medicine 2018 Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, Carvajal L, Cao P, Pauly JM, Kerr AB, Park I, Slater JB, Nelson SJ, Munster PN, Aggarwal R, Kurhanewicz J, Vigneron DB
• Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.
  Scientific reports 2018 Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN
• HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
  Oncotarget 2017 Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN
• Host histone acetylation unlocks HDAC inhibitor potential.
  Oncotarget 2017 Terranova-Barberio M, Thomas S, Munster PN
• Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
  Breast cancer research : BCR 2017 Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, …
• Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer.
  Plastic and reconstructive surgery 2017 Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN
• Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN
• What advanced cancer patients with limited treatment options know about clinical research: a qualitative study.
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2017 Garrett SB, Koenig CJ, Trupin L, Hlubocky FJ, Daugherty CK, Reinert A, Munster P, Dohan D
• A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
  Blood 2017 Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R
• Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J
• Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
  Cancer immunology research 2017 Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-…
• Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
  American heart journal 2017 Guglin M, Munster P, Fink A, Krischer J
• 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS
• Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
  Cancer management and research 2017 Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ
• Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN
• Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-…
• Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
  Cancer chemotherapy and pharmacology 2016 Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S
• Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome.
  JAMA oncology 2016 Munster PN
• Interest in initiating an early phase clinical trial: results of a longitudinal study of advanced cancer patients.
  Psycho-oncology 2016 Dunn LB, Wiley J, Garrett S, Hlubocky F, Daugherty C, Trupin L, Munster P, Dohan D
• Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
  Immunotherapy 2016 Terranova-Barberio M, Thomas S, Munster PN
• A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
  Annals of oncology : official journal of the European Society for Medical Oncology 2016 Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN
• A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
  Breast cancer research and treatment 2016 Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN
• Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
  Annals of oncology : official journal of the European Society for Medical Oncology 2015 Rodriguez-Wallberg K, Turan V, Munster P, Oktay K
• First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock…
• Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.
  Breast cancer research and treatment 2015 Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP
• Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.
  European journal of cancer (Oxford, England : 1990) 2015 Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S
• A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA
• A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
  Cancer 2015 Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN
• Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
  Cancer discovery 2015 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA
• More Options for Fertility Preservation for Patients With Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Munster PN
• Ovarian protection during adjuvant chemotherapy.
  The New England journal of medicine 2015 Oktay K, Rodriguez-Wallberg K, Munster P
• Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
  Breast cancer research : BCR 2015 Raha P, Thomas S, Thurn KT, Park J, Munster PN
• Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, …
• Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
  Epigenomics 2015 Park J, Thomas S, Munster PN
• Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
  Cancer chemotherapy and pharmacology 2014 Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P
• New protein kinase inhibitors in breast cancer: afatinib and neratinib.
  Expert opinion on pharmacotherapy 2014 Zhang X, Munster PN
• Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM
• Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.
  Cancer chemotherapy and pharmacology 2014 Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R
• Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL
• A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
  Cancer chemotherapy and pharmacology 2013 Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A
• Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate.
  Science translational medicine 2013 Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP…
• Histone deacetylase regulation of ATM-mediated DNA damage signaling.
  Molecular cancer therapeutics 2013 Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN
• Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.
  PloS one 2013 Thomas S, Thurn KT, Raha P, Chen S, Munster PN
• Fertility preservation and breast cancer: A complex problem.
  Oncology (Williston Park, N.Y.) 2013 Munster PN
• Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB
• Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
  Annals of oncology : official journal of the European Society for Medical Oncology 2013 Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP
• Developing safety criteria for introducing new agents into neoadjuvant trials.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P…
• Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.
  Blood 2012 Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE
• The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.
  Breast cancer research and treatment 2012 Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M
• A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
  Breast cancer research and treatment 2012 Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T
• Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE
• Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
  British journal of cancer 2011 Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI
• Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
  Expert opinion on investigational drugs 2011 Munster PN, Daud AI
• Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.
  Epigenomics 2011 Raha P, Thomas S, Munster PN
• Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.
  Annals of oncology : official journal of the European Society for Medical Oncology 2011 Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E, Fumoleau P, Ward R, Bardy-Bouxin N, Leip E, Turnbull K, Zacharchuk C, Epstein RJ
• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
  British journal of cancer 2011 Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE
• Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
  American journal of medical genetics. Part C, Seminars in medical genetics 2011 Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH
• Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
  Future oncology (London, England) 2011 Thurn KT, Thomas S, Moore A, Munster PN
• A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M
• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
  British journal of cancer 2009 Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A
• Estradiol in breast cancer treatment: reviving the past.
  JAMA 2009 Munster PN, Carpenter JT
• Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
  Melanoma research 2009 Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI
• Cognitive functioning in breast cancer survivors: a controlled comparison.
  Cancer 2009 Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB
• Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM
• HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.
  Molecular cancer therapeutics 2009 Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN
• A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA
• Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D
• Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN
• Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
  Cancer letters 2009 Thomas S, Munster PN
• Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R
• Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
  Cancer 2008 Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D
• Activated stat-3 in melanoma.
  Cancer control : journal of the Moffitt Cancer Center 2008 Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI
• Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory.
  Journal of pain and symptom management 2008 Donovan KA, Jacobsen PB, Small BJ, Munster PN, Andrykowski MA
• Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach.
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007 Gwede CK, Small BJ, Munster PN, Andrykowski MA, Jacobsen PB
• Fatigue after treatment for early stage breast cancer: a controlled comparison.
  Cancer 2007 Jacobsen PB, Donovan KA, Small BJ, Jim HS, Munster PN, Andrykowski MA
• Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI
• Physical symptoms/side effects during breast cancer treatment predict posttreatment distress.
  Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 2007 Jim HS, Andrykowski MA, Munster PN, Jacobsen PB
• Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
  Cancer chemotherapy and pharmacology 2007 Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A
• Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment.
  Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2007 Donovan KA, Small BJ, Andrykowski MA, Munster P, Jacobsen PB
• Discussion of fertility preservation with newly diagnosed patients: oncologists' views.
  Journal of cancer survivorship : research and practice 2007 Quinn GP, Vadaparampil ST, Gwede CK, Miree C, King LM, Clayton HB, Wilson C, Munster P
• First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW
• ABCG2 expression, function, and promoter methylation in human multiple myeloma.
  Blood 2006 Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM
• Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM
• Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
  Molecular cancer therapeutics 2006 Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN
• Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
  Cancer control : journal of the Moffitt Cancer Center 2006 Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI
• Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM
• Arzoxifene: the development and clinical outcome of an ideal SERM.
  Expert opinion on investigational drugs 2006 Munster PN
• Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma.
  Cancer 2005 Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB
• In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.
  Molecular cancer therapeutics 2005 Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN
• Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN
• Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model.
  DNA and cell biology 2005 Xu Q, Brabham JG, Zhang S, Munster P, Fields K, Zhao RJ, Yu H
• Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.
  Cancer research 2005 Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN
• Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D
• Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
  Journal of cellular biochemistry 2004 Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN
• Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C
• Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer.
  Cancer control : journal of the Moffitt Cancer Center 2002 Minton SE, Munster PN
• Improving breast cancer care.
  Cancer control : journal of the Moffitt Cancer Center 2002 Munster PN
• Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
  Oncogene 2002 Basso AD, Solit DB, Munster PN, Rosen N
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
  Cancer research 2001 Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM
• Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
  Cancer control : journal of the Moffitt Cancer Center 2001 Munster PN, Horton J
• Predictive factor for the response to adjuvant therapy with emphasis in breast cancer.
  Breast cancer research : BCR 2001 Munster PN, Norton L
• New drugs in gynecologic cancer.
  Current treatment options in oncology 2001 Daud A, Munster P, Munster P, Spriggs DR
• A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.
  Chemistry & biology 2001 Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N
• Update on the management of advanced breast cancer.
  Oncology (Williston Park, N.Y.) 1999 Fornier M, Munster P, Seidman AD